

09/14/00
1c923 U.S. PTO

09-15-00

A

Attorney Docket No.: 6028.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Express Mail Label No. EL636737496US
Date of Deposit September 14, 2000

1c918 U.S. PTO
09/661696
09/14/00

Sir:

This is a request for filing a patent application under 37 C.F.R. 1.53(b) of
Applicant(s): Tina Meinertz Andersen

Title: Composition Containing a Meiosis Activating Substance
11 pages of specification 3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

| | |
|---|----------|
| Basic Fee: | \$690.00 |
| Total Claims: $19 - 20 = 0 \times 18 =$ | \$0 |
| Independent Claims: $1 - 3 = 0 \times 78 =$ | \$0 |
| Total Fee: | \$690.00 |

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of
North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$690, to Novo Nordisk of North
America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: September 14, 2000

Valetta A. Gregg

Valeta A. Gregg, Reg. No. 35,127
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231



Re: U.S. Patent Application for
Title: Composition Containing a Meiosis Activating Substance
Applicants: Tina Meinertz Andersen

Sir:

Express Mail Label No. EL636737496US

Date of Deposit : September 14, 2000

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Unexecuted Combined Declaration and Power of Attorney
4. Preliminary Amendment

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Miriam Kelly

(Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123

09661696-091400